Mark Angland
Senior Associate
Norton Rose Fulbright US LLP
Related services and key industries
Biography
Mark Angland is an associate in the Commercial Litigation and the Antitrust and Competition groups. He has represented clients in a variety of antitrust matters including multi-district litigations and investigations by the U.S. Department of Justice Antitrust division and Federal Trade Commission. Mark has also assisted clients with obtaining competition approvals from antitrust agencies for complex M&A transactions by preparing Hart-Scott-Rodino Act filings and responding to Second Requests and Voluntary Request Letters.
Mark has represented clients in litigations and government investigations related to a variety of industry sectors including pharmaceuticals, healthcare, and technology.
Professional experience
Collapse allJD, Georgetown University Law Center, 2016
BS, Neuroscience, University of Rochester, 2013
After law school, Mark was a research fellow for the American Antitrust Institute. During law school, Mark was a legal intern for the Federal Trade Commission.
- District of Columbia Bar
- New York State Bar
- Legal 500 US, Recommended Lawyer, Antitrust: Civil litigation/class actions: Defense, 2024
- Contributor, "Understanding the FTC's Monetary Equitable Remedies Under Section 13(b) for Antitrust Violations," American Bar Association Antitrust Magazine, December 13, 2019
- Co-author, "Americas Antitrust Review 2020 - United States: Energy," GCR Insight, Law Business Research, September 20, 2019
- Co-author with Amanda Wait, "FTC Consent Orders with Firewalls," prepared in connection with American Bar Association, Section of Antitrust Law, 67th Annual Spring Meeting, March 27, 2019
- Author, "Staples/Essendant: Highlighting Different Approaches to Vertical Merger Reviews" The Threshold, Vol. 14, Issue 2, Spring 2019
- Vice Chair of ABA Antitrust Section Transportation and Energy Industries Committee
- New York Bar Association
- District of Columbia Bar Association
Insights
FTC and DOJ issue revised Merger Guidelines
Publication | December 19, 2023
New barriers to pharma deals: FTC challenges Amgen / Horizon merger without alleging product overlaps
Publication | May 25, 2023
US FTC pharma merger workshop
Publication | June 17, 2022